New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
07:15 EDTBCLI, ATHX, NBS, PSTI, CUR, OSIRRRY Publications to host a summit
8th Annual New York Stem Cell Summit '13 is being held in New York on February 19.
News For OSIR;PSTI;ATHX;CUR;NBS;BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 29, 2015
16:23 EDTNBSNeoStem announces randomization of first patient in Intus Phase 3 clinical trial
Subscribe for More Information
09:19 EDTATHXAthersys to hold a conference call
Chairman & CEO Van Bokkelen discusses the recently announced interim results of the company's exploratory Phase 2 clinical study of the intravenous administration of MultiStem(R) cell therapy on a conference call to be held on April 29 at 2 pm. Webcast Link
08:33 EDTNBSCryoport supports NeoStem's Intus study for metastatic melanoma treatment
Cryoport (CYRX) is supporting NeoStem's (NBS) Intus Study to evaluate its lead cancer immunotherapy, NBS20, for the treatment of metastatic melanoma. NeoStem is developing an autologous immunotherapy that uses a patient's own tumor cells to maximize the immune system's ability to identify and eliminate the cancer initiating cells that NeoStem believes are capable of reconstituting and developing new tumors. The Intus Study for the treatment of metastatic melanoma has received Special Protocol Assessment and the program has received Fast Track and Orphan Drug Designations from the FDA. Cryoport's cryogenic logistics solution is providing comprehensive support for NeoStem's Intus Study, which is advancing to a Phase 3 trial.
April 28, 2015
10:05 EDTCUROn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:37 EDTCURNeuralstem initiated with a Buy at MLV & Co.
Subscribe for More Information
April 27, 2015
07:35 EDTNBSNeoStem says NBS20 receives ATMP classification from EMA
Subscribe for More Information
April 22, 2015
05:48 EDTATHXStocks with implied volatility movement; CSX ATHX
Stocks with implied volatility movement; CSX (CSX) 40, Athersys (ATHX) 151 according to iVolatility.
April 21, 2015
09:45 EDTATHXMaxim still bullish on Athersys, says data show 'strong signal'
Maxim analyst Jason Kolbert told investors today that he remains bullish on Athersys after the company announced Friday morning its stroke trial missed the primary and secondary endpoints. Kolbert says the data show MultiStem appears to be able to extend the treatment window in stroke from a few hours to 36 hours, which he calls "dramatic." He views the data as showing a "strong signal," and added "it seems that no one wants to hear or look" at it. The analyst expects Athersys to announce plans to move forward in a Phase IIb/III global trial in the U.S., Europe and Japan. He pointed out that Maxim hopes to announce next week a series of conference calls with Athersys management and experts. Kolbert kept a Buy rating on Athersys with a $9 price target. The stock is trading down 3c to $1.32 in early trading.
09:22 EDTBCLIOn The Fly: Pre-market Movers
Subscribe for More Information
06:58 EDTBCLIBrainStorm NurOwn demonstrates statistically significant effects in ALS patients
BrainStorm Cell Therapeutics is presenting results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis, or ALS, at a poster session today at the American Academy of Neurology annual meeting, taking place in Washington D.C. In addition to previously disclosed topline results, further data and analyses are being presented for the first time. Among the new results is a piecewise linear regression analysis of all subjects who received intrathecal, or IT, administration in the phase 2a study and the prior phase 1/2 study. At six months post-treatment, there was a statistically significant improvement in the estimated rate of decline in Forced Vital Capacity, or FVC, from -5.1% per month pre-treatment to -1.2% per month post-treatment and a nearly significant improvement in the rate of ALS Functional Rating Score-Revised, or ALSFRS-R, decline, from -1.2 points per month pre-treatment to -0.6 points per month post treatment. Also being reported for the first time are local positive effects of intramuscular administration. 3D volumetric analysis using MRI revealed an improvement in the rate of decline in muscle mass in the right arm, the site of NurOwn administration, through one month post-treatment, as compared to the left arm. Electromyography demonstrated a trend of stabilization of the compound motor axon potential in the right musculocutaneous nerve as compared to deterioration observed in the left.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use